Skip to main content
. 2020 Aug 18;4(16):3864–3874. doi: 10.1182/bloodadvances.2020001904

Figure 2.

Figure 2.

Impact of MRD on the outcome of patients with AML in the context of ELN2017 risk classification. CIR and OS of patients who were MRD categorized according to the ELN2017 classification compared with BAALC MRD+ (A-B) and MN1 MRD+ (C-D) patients or those with NPM1-mutated MRD (E-F).